查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971794

慢性肾臟病市场分析及预测（至2035年）：按类型、产品类型、服务、技术、组件、应用、最终用户、设备、功能和解决方案划分

Chronic Kidney Disease Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Device, Functionality, Solutions
出版日期: | 出版商: Global Insight Services | 英文 359 Pages | 商品交期: 3-5个工作天内

价格
简介目录

慢性肾臟病（CKD）市场预计将从2024年的529亿美元成长到2034年的1,028亿美元，复合年增长率约为6.9%。 CKD市场涵盖肾功能衰退的诊断、治疗和管理，包括药物、透析设备和移植服务。由于慢性肾臟病老化和文明病， CKD盛行率不断上升，推动了对创新治疗方法和早期检测工具的需求。对个人化医疗和经济高效护理模式的重视正在塑造市场动态，而诊断和治疗技术的进步则提供了巨大的成长机会。

由于治疗方法的进步和疾病盛行率的上升，慢性肾臟病市场预计将迎来强劲增长。其中，促红血球生成素刺激剂细分市场占据主导地位，该细分市场可有效治疗与肾臟病相关的贫血。肾素-血管收缩素-醛固酮系统抑制剂紧随其后，由于其在延缓疾病进展方面的作用，需求量不断增长。透析领域也展现出巨大的潜力，其中血液透析表现最佳，反映了其广泛的应用和显着的疗效。腹膜透析位居第二，因其便利性和居家治疗选择而日益普及。穿戴式和携带式透析设备等创新技术有望彻底改变患者护理，从而提高患者的生活品质和治疗依从性。诊断领域，特别是生物标记发现和检验细分市场，正在快速发展，为早期检测和个人化治疗策略提供了可能。这种充满活力的市场环境为相关人员投资新型治疗方法和技术提供了绝佳的机会。

市场区隔
按类型 糖尿病肾臟病、高血压肾臟病、肾丝球肾炎、多囊性肾病变、慢性肾臟病－矿物质和骨骼疾病
产品 药品、透析机、肾臟移植相关产品、诊断设备、营养补充品
服务 透析服务、居家医疗保健服务、远距医疗服务、营养咨询、病患教育服务
科技 透析技术、生物标记技术、基因体学、蛋白质体学、奈米技术
成分 软体、硬体、耗材和试剂
应用 诊断、治疗、监测和监视
最终用户 医院、肾臟护理中心、居家医疗机构、研究机构、大学附设医院
装置 血液透析机、腹膜透析机、穿戴式人工肾臟、连续性肾臟替代疗法装置
功能 自动化系统、手动系统、智慧型系统
解决方案 综合护理解决方案、慢性病管理和病人参与解决方案

市场概况：

慢性肾臟病(CKD) 市场正经历着市场份额的动态变化，这主要得益于创新产品的推出和策略性定价模式的优化。製药公司正致力于开发新型疗法以满足未被满足的医疗需求，并扩大市场份额。定价策略也在不断优化，以确保药物的可及性并维持盈利。此外，生技公司与医疗服务提供者之间的合作也迅速增加，以加速最先进治疗的应用。 CKD 市场的竞争异常激烈，主要企业在研发方面投入大量资金以获得竞争优势。法规结构，尤其是在北美和欧洲，透过严格的指导方针影响产品核可和市场准入，对塑造市场动态至关重要。对竞争对手的比较分析凸显了对个人化医疗和生物製药日益增长的关注。在患病率不断上升、诊断技术不断进步以及一系列前景广阔的治疗方法的推动下，该市场正呈现出成长的迹象。

主要趋势和驱动因素：

慢性肾臟病(CKD) 市场正经历着变革性成长，这主要得益于几个关键趋势和驱动因素。人口老化以及糖尿病和高血压发病率的上升导致 CKD 盛行率不断攀升，是推动市场成长的关键因素。这些疾病是 CKD 的主要风险因素，因此亟需加强检测和治疗方案。诊断工具和治疗调查方法的技术进步正在显着影响市场。基于生物标记的诊断和穿戴式健康监测设备等创新技术，使得早期检测和个人化治疗方案成为可能。人工智慧 (AI) 在医疗保健领域的应用，进一步完善了诊断和治疗方案。政府主导和医疗保健政策正在推动早期筛检和提高公众意识，从而促进市场成长。健保报销政策也日趋优惠，让病患更容易获得先进的治疗方案。此外，对居家透析和远端医疗服务的日益重视，扩大了患者获得医疗保健服务的管道，为市场扩张提供了广泛的机会。

限制与挑战：

慢性肾臟病（CKD）市场面临许多重大限制和挑战。其中一个关键限制因素是治疗高成本，限制了患者的就医途径，尤其是在低收入地区。这种经济障碍往往导致诊断和治疗延误，加剧疾病进展。此外，肾臟科医师和专科医护人员长期短缺，导致病患管理和照护不足。这种短缺影响了及时介入和製定全面治疗方案。同时，CKD市场也面临患者对早期症状和预防措施认知不足的问题，导致患者确诊时往往已处于晚期。监管环境也是一大挑战，新治疗方法的严格核准流程减缓了市场准入和创新。最后，缺乏标准化的治疗通讯协定也阻碍了市场发展，导致护理和治疗结果不一致。这些挑战迭加在一起，阻碍了CKD市场有效解决方案的成长和开发。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 糖尿病肾臟病
    • 高血压肾臟病
    • 肾丝球肾炎
    • 多囊肾
    • 慢性肾臟病－矿物质和骨骼代谢紊乱
  • 市场规模及预测：依产品划分
    • 製药
    • 透析机
    • 肾臟移植产品
    • 诊断设备
    • 营养补充品
  • 市场规模及预测：依服务划分
    • 透析服务
    • 家庭医疗保健服务
    • 远端医疗服务
    • 营养咨询
    • 病人教育服务
  • 市场规模及预测：依技术划分
    • 透析技术
    • 生物标记技术
    • 基因组学
    • 蛋白质体学
    • 奈米科技
  • 市场规模及预测：依组件划分
    • 软体
    • 硬体
    • 消耗品
    • 试剂
  • 市场规模及预测：依应用领域划分
    • 诊断
    • 治疗
    • 监测
    • 调查
  • 市场规模及预测：依最终用户划分
    • 医院
    • 肾臟护理中心
    • 居家医疗环境
    • 研究所
    • 学术医疗中心
  • 市场规模及预测：依设备划分
    • 血液透析机
    • 腹膜透析机
    • 穿戴式人工肾臟
    • 连续性肾臟替代治疗装置
  • 市场规模及预测：依功能划分
    • 自动化
    • 手动的
    • 智慧系统
  • 市场规模及预测：按解决方案划分
    • 综合护理解决方案
    • 慢性病照护管理
    • 病人参与方案

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Akebia Therapeutics
  • Reata Pharmaceuticals
  • ChemoCentryx
  • Otsuka Pharmaceutical
  • Keryx Biopharmaceuticals
  • Vifor Pharma
  • Calliditas Therapeutics
  • Relypsa
  • Tricida
  • FibroGen
  • AstraZeneca
  • Cara Therapeutics
  • Rockwell Medical
  • Angion Biomedica
  • Chinook Therapeutics

第九章：关于我们

简介目录
Product Code: GIS33710

Chronic Kidney Disease Market is anticipated to expand from $52.9 billion in 2024 to $102.8 billion by 2034, growing at a CAGR of approximately 6.9%. The Chronic Kidney Disease (CKD) Market encompasses the diagnosis, treatment, and management of kidney function deterioration. It includes pharmaceuticals, dialysis equipment, and transplant services. Rising CKD prevalence, driven by aging populations and lifestyle diseases, is fueling demand for innovative therapies and early detection tools. Emphasis on personalized medicine and cost-effective care models is shaping market dynamics, with technological advancements in diagnostics and treatment offering significant growth opportunities.

The Chronic Kidney Disease Market is poised for robust growth, propelled by advancements in treatment modalities and increasing prevalence of the disease. The pharmaceuticals segment dominates, with the erythropoietin-stimulating agents sub-segment leading due to their efficacy in managing anemia associated with kidney disease. Renin-angiotensin-aldosterone system inhibitors follow, driven by their role in slowing disease progression. The dialysis segment also shows significant promise, with hemodialysis emerging as the top-performing sub-segment, reflecting its widespread use and effectiveness. Peritoneal dialysis is the second-highest performer, gaining traction for its convenience and home-based treatment options. Innovative technologies, such as wearable and portable dialysis devices, are set to revolutionize patient care, enhancing quality of life and compliance. The diagnostics segment, particularly the biomarker discovery and validation sub-segment, is rapidly advancing, offering potential for early detection and personalized treatment strategies. This dynamic landscape presents lucrative opportunities for stakeholders to invest in novel therapies and technologies.

Market Segmentation
TypeDiabetic Kidney Disease, Hypertensive Kidney Disease, Glomerulonephritis, Polycystic Kidney Disease, Chronic Kidney Disease-Mineral and Bone Disorder
ProductPharmaceuticals, Dialysis Equipment, Kidney Transplantation Products, Diagnostic Instruments, Nutritional Supplements
ServicesDialysis Services, Home Healthcare Services, Telemedicine Services, Nutritional Counseling, Patient Education Services
TechnologyDialysis Technology, Biomarker Technology, Genomics, Proteomics, Nanotechnology
ComponentSoftware, Hardware, Consumables, Reagents
ApplicationDiagnosis, Treatment, Monitoring, Research
End UserHospitals, Renal Care Centers, Homecare Settings, Research Institutes, Academic Medical Centers
DeviceHemodialysis Machines, Peritoneal Dialysis Machines, Wearable Artificial Kidneys, Continuous Renal Replacement Therapy Devices
FunctionalityAutomated, Manual, Smart Systems
SolutionsIntegrated Care Solutions, Chronic Care Management, Patient Engagement Solutions

Market Snapshot:

The Chronic Kidney Disease (CKD) market is witnessing a dynamic shift in market share, driven by innovative product launches and strategic pricing models. Pharmaceutical companies are focusing on developing novel therapeutics that address unmet patient needs, thereby enhancing their market presence. Pricing strategies are being optimized to ensure accessibility while maintaining profitability. The market is also characterized by a surge in collaborations between biotech firms and healthcare providers, aiming to expedite the introduction of cutting-edge treatments. Competition in the CKD market is intense, with leading companies investing heavily in R&D to gain a competitive edge. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics, with stringent guidelines influencing product approvals and market entry. Benchmarking against competitors reveals a focus on personalized medicine and biologics. The market is poised for growth, driven by increasing prevalence rates, advancements in diagnostic technologies, and a robust pipeline of potential therapies.

Geographical Overview:

The Chronic Kidney Disease (CKD) market exhibits diverse growth trends across various regions, each presenting unique opportunities. North America remains a dominant force, driven by advanced healthcare infrastructure and heightened awareness of CKD management. The region's proactive approach to early diagnosis and treatment bolsters market growth. Europe follows closely, with robust healthcare policies and increasing prevalence of lifestyle-related diseases contributing to market expansion. The Asia Pacific region is witnessing rapid growth, fueled by rising healthcare expenditure and a growing patient pool. Emerging economies such as India and China are at the forefront, driven by improving healthcare access and increasing CKD awareness. Latin America is also experiencing growth, supported by government initiatives and healthcare reforms. Meanwhile, the Middle East & Africa region holds potential, with increasing investments in healthcare infrastructure aiming to address the rising CKD burden. These regions present lucrative opportunities for stakeholders to capitalize on emerging market dynamics.

Key Trends and Drivers:

The Chronic Kidney Disease (CKD) market is experiencing transformative growth driven by several key trends and drivers. The rising prevalence of CKD, fueled by an aging population and increasing incidence of diabetes and hypertension, is a primary driver. These conditions are major risk factors for CKD, necessitating enhanced detection and treatment options. Technological advancements in diagnostic tools and treatment methodologies are significantly impacting the market. Innovations such as biomarker-based diagnostics and wearable health monitoring devices are enabling earlier detection and personalized treatment approaches. The integration of artificial intelligence in healthcare is further refining diagnosis and treatment plans. Government initiatives and healthcare policies are promoting early screening and awareness programs, propelling market growth. Reimbursement policies are also becoming more favorable, easing access to advanced treatments. Additionally, the growing emphasis on home-based dialysis and telemedicine services is expanding patient access to care, offering lucrative opportunities for market expansion.

Restraints and Challenges:

The Chronic Kidney Disease (CKD) market encounters several significant restraints and challenges. A primary constraint is the high cost of treatment options, which limits accessibility for patients, particularly in low-income regions. This financial barrier often results in delayed diagnosis and treatment, exacerbating disease progression. Moreover, there is a persistent shortage of nephrologists and specialized healthcare providers, leading to inadequate patient management and care. This scarcity affects timely interventions and comprehensive treatment plans. Additionally, the CKD market struggles with low patient awareness about early symptoms and preventive measures, causing late-stage diagnoses. The regulatory landscape presents another challenge, with stringent approval processes for new therapies, delaying market entry and innovation. Finally, the market is hindered by the lack of standardized treatment protocols, which causes variability in care and outcomes. These challenges collectively impede the growth and development of effective solutions in the CKD market.

Key Players:

Akebia Therapeutics, Reata Pharmaceuticals, ChemoCentryx, Otsuka Pharmaceutical, Keryx Biopharmaceuticals, Vifor Pharma, Calliditas Therapeutics, Relypsa, Tricida, FibroGen, AstraZeneca, Cara Therapeutics, Rockwell Medical, Angion Biomedica, Chinook Therapeutics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Diabetic Kidney Disease
    • 4.1.2 Hypertensive Kidney Disease
    • 4.1.3 Glomerulonephritis
    • 4.1.4 Polycystic Kidney Disease
    • 4.1.5 Chronic Kidney Disease-Mineral and Bone Disorder
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Pharmaceuticals
    • 4.2.2 Dialysis Equipment
    • 4.2.3 Kidney Transplantation Products
    • 4.2.4 Diagnostic Instruments
    • 4.2.5 Nutritional Supplements
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Dialysis Services
    • 4.3.2 Home Healthcare Services
    • 4.3.3 Telemedicine Services
    • 4.3.4 Nutritional Counseling
    • 4.3.5 Patient Education Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Dialysis Technology
    • 4.4.2 Biomarker Technology
    • 4.4.3 Genomics
    • 4.4.4 Proteomics
    • 4.4.5 Nanotechnology
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Software
    • 4.5.2 Hardware
    • 4.5.3 Consumables
    • 4.5.4 Reagents
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Diagnosis
    • 4.6.2 Treatment
    • 4.6.3 Monitoring
    • 4.6.4 Research
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Renal Care Centers
    • 4.7.3 Homecare Settings
    • 4.7.4 Research Institutes
    • 4.7.5 Academic Medical Centers
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Hemodialysis Machines
    • 4.8.2 Peritoneal Dialysis Machines
    • 4.8.3 Wearable Artificial Kidneys
    • 4.8.4 Continuous Renal Replacement Therapy Devices
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Automated
    • 4.9.2 Manual
    • 4.9.3 Smart Systems
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Integrated Care Solutions
    • 4.10.2 Chronic Care Management
    • 4.10.3 Patient Engagement Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Device
      • 5.2.1.9 Functionality
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Device
      • 5.2.2.9 Functionality
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Device
      • 5.2.3.9 Functionality
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Device
      • 5.3.1.9 Functionality
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Device
      • 5.3.2.9 Functionality
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Device
      • 5.3.3.9 Functionality
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Device
      • 5.4.1.9 Functionality
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Device
      • 5.4.2.9 Functionality
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Device
      • 5.4.3.9 Functionality
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Device
      • 5.4.4.9 Functionality
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Device
      • 5.4.5.9 Functionality
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Device
      • 5.4.6.9 Functionality
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Device
      • 5.4.7.9 Functionality
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Device
      • 5.5.1.9 Functionality
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Device
      • 5.5.2.9 Functionality
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Device
      • 5.5.3.9 Functionality
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Device
      • 5.5.4.9 Functionality
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Device
      • 5.5.5.9 Functionality
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Device
      • 5.5.6.9 Functionality
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Device
      • 5.6.1.9 Functionality
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Device
      • 5.6.2.9 Functionality
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Device
      • 5.6.3.9 Functionality
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Device
      • 5.6.4.9 Functionality
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Device
      • 5.6.5.9 Functionality
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Akebia Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Reata Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 ChemoCentryx
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Otsuka Pharmaceutical
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Keryx Biopharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Vifor Pharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Calliditas Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Relypsa
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Tricida
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 FibroGen
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 AstraZeneca
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cara Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Rockwell Medical
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Angion Biomedica
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Chinook Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us